Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

J Biomed Sci. 2019 Dec 5;26(1):96. doi: 10.1186/s12929-019-0588-8.


Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

Keywords: Cancer immunotherapy; Checkpoint inhibitor; PD-1 PD-L1 signaling.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • B7-H1 Antigen / genetics*
  • Biomarkers, Tumor / therapeutic use*
  • Humans
  • Immunotherapy*
  • Neoplasms / genetics
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / genetics*


  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor